IGF-1 LR3 1 mg

DRAGON PHARMA IGF-1 LR3

Dragon Pharma IGF-1 LR3 1 mg represents the pinnacle of muscle growth and performance enhancement technology for serious athletes, bodybuilders, and fitness enthusiasts in the United States. This advanced recombinant analog of Insulin-Like Growth Factor 1 (IGF-1) features the revolutionary Long R3 modification—substitution of arginine at position 3 for glutamic acid and a 13-amino acid extension peptide—resulting in dramatically reduced binding to IGF binding proteins (IGFBPs) and extended half-life. Each 2 mL vial contains 1 mg of pharmaceutical-grade lyophilized IGF-1 LR3 powder, manufactured under strict pharmaceutical standards to ensure maximum purity, stability, and biological activity. Third-party laboratory testing confirms exceptional potency at 1.05 mg per vial, demonstrating Dragon Pharma's commitment to quality that exceeds labeled claims and delivers reliable, predictable results for muscle hyperplasia, nutrient partitioning, and recovery enhancement.

DRUG COMPOSITION

Each vial contains 1 mg of IGF-1 Long R3 analog as a white lyophilized powder. The molecular structure consists of 83 amino acids with two critical modifications: substitution of glutamic acid for arginine at position 3 (R3), and addition of a 13-amino acid extension peptide at the N-terminus. These modifications reduce binding affinity for IGF binding proteins (IGFBPs) by approximately 100-fold compared to native IGF-1, resulting in significantly increased bioavailability and extended half-life. The product contains no additional excipients, fillers, or preservatives, ensuring maximum purity and minimizing potential allergic reactions. The lyophilization process removes water through freeze-drying, resulting in a stable powder that maintains potency throughout its 24-month shelf life when stored properly at 2-8°C.

PHARMACEUTICAL FORM

Sterile lyophilized powder for injection in a 2 mL glass vial sealed with a gray rubber stopper and silver aluminum cap. The lyophilized form offers superior stability compared to liquid preparations, with extended shelf life and reduced risk of microbial contamination or peptide degradation. The powder reconstitutes quickly with bacteriostatic acetic acid (0.6% acetic acid) or specialized IGF-1 reconstitution solution, forming a clear, colorless solution suitable for subcutaneous or intramuscular injection. Each vial is individually packaged with tamper-evident seals and includes batch-specific quality control documentation. The 2 mL volume allows for flexible reconstitution concentrations based on individual dosing preferences, typically reconstituting with 1-2 mL for concentrations of 0.5-1 mg/mL.

PHARMACEUTICAL GROUP AND ATC CODE

IGF-1 LR3 belongs to the therapeutic category of other hormones and synthetic substitutes (ATC code: H03AX). According to the WHO Anatomical Therapeutic Chemical Classification System, it falls under miscellaneous hormones. Specifically, it's classified as an insulin-like growth factor analog. In sports medicine and performance enhancement, it's categorized as a potent anabolic growth factor with hyperplastic (new cell creation) properties distinct from traditional hypertrophic (cell enlargement) anabolics. The Long R3 modification creates a unique pharmacological profile with reduced protein binding and enhanced bioavailability compared to native IGF-1 or IGF-1 DES.

PHARMACOLOGICAL PROPERTIES

IGF-1 LR3 exerts its effects through binding to the IGF-1 receptor (IGF-1R), triggering intracellular signaling cascades including the PI3K/AKT/mTOR pathway that promotes protein synthesis, cell proliferation, and inhibition of apoptosis. The Long R3 modification dramatically reduces binding to IGF binding proteins (IGFBPs), increasing free IGF-1 bioavailability by approximately 100-fold compared to native IGF-1. According to research published in the Journal of Endocrinology, IGF-1 promotes muscle hyperplasia (creation of new muscle cells) rather than just hypertrophy (enlargement of existing cells), representing a fundamental difference from traditional anabolic steroids. The peptide enhances glucose and amino acid uptake into muscle cells, stimulates satellite cell activation and differentiation, promotes collagen synthesis in connective tissues, and enhances lipolysis while inhibiting lipogenesis.

THERAPEUTICAL INDICATIONS

Dragon Pharma IGF-1 LR3 1 mg is indicated for: promotion of muscle hyperplasia (new muscle fiber creation) in advanced bodybuilders, enhancement of nutrient partitioning and anabolic efficiency, acceleration of recovery from intense training and injury, reduction of adipose tissue particularly stubborn fat deposits, improvement of connective tissue strength and joint health, support of localized muscle growth through site-specific administration, enhancement of insulin sensitivity and glucose metabolism, and general anabolic support during muscle-building phases. It's particularly valuable for bodybuilders seeking to break through genetic plateaus, athletes recovering from injuries, individuals with stubborn fat areas resistant to diet and exercise, and advanced users looking for hyperplastic rather than just hypertrophic growth.

DOSES AND METHOD OF ADMINISTRATION

Reconstitute the 1 mg vial with 1 mL of bacteriostatic acetic acid (0.6% acetic acid) for optimal stability, achieving a concentration of 1 mg/mL. Standard dosing protocols range from 20-80 mcg daily, typically administered as a single dose or divided into two doses. For hyperplasia and muscle growth: 40-80 mcg daily, often administered post-workout. For nutrient partitioning and fat loss: 20-40 mcg daily, typically administered upon waking in a fasted state. For localized growth: 20-40 mcg injected intramuscularly into target muscle groups immediately post-training. Administration should be subcutaneous for systemic effects or intramuscular for localized effects, rotating injection sites to prevent tissue irritation. Treatment cycles typically last 4-6 weeks with equal time off to prevent receptor desensitization.

CYCLE/STACKING

IGF-1 LR3 stacks synergistically with various compounds to maximize specific outcomes. Combine with Insulin (when used by experienced individuals) for enhanced nutrient uptake and anabolic synergy through complementary pathways. Stack with Testabol 400 for amplified muscle growth through combined hyperplastic (IGF-1) and hypertrophic (testosterone) mechanisms. For enhanced fat loss during cutting, add T3 to increase metabolic rate while preserving muscle tissue. During muscle-building phases, combine with Deca 300 for connective tissue support alongside muscle growth. For comprehensive recovery and nutrient partitioning, include MK-677 to elevate endogenous IGF-1 levels between IGF-1 LR3 cycles.

POST CYCLE THERAPY

IGF-1 LR3 serves as a valuable adjunct during post-cycle therapy by helping maintain muscle tissue and metabolic rate when transitioning off anabolic compounds. Unlike traditional anabolics that suppress the HPTA axis, IGF-1 works through different pathways and may actually support natural hormone production through improved insulin sensitivity and metabolic health. Administer 20-40 mcg daily during the first 2-4 weeks of PCT to help preserve hard-earned muscle mass while enhancing fat loss that often becomes challenging during hormonal transitions. The improved nutrient partitioning helps maintain training performance despite reduced androgen levels. However, use cautiously as IGF-1 may affect glucose metabolism—monitor blood sugar closely during PCT when insulin sensitivity may be changing. Many advanced users implement IGF-1 LR3 during the "bridge" period between cycles to maintain gains.

SIDE EFFECTS

Common side effects include hypoglycemia (low blood sugar) due to enhanced glucose uptake, particularly when administered without adequate carbohydrate intake. Other frequent effects include temporary water retention, joint stiffness or pain, numbness or tingling in extremities, increased hunger, and potential organ enlargement with prolonged high-dose use. Injection site reactions may include redness, swelling, or itching. Unlike anabolic steroids, IGF-1 LR3 doesn't cause androgenic side effects (hair loss, acne, prostate issues) or estrogenic side effects (gynecomastia, water retention). However, it may theoretically increase cancer risk due to its proliferative effects on all cell types. Most side effects are dose-dependent and manageable with proper protocol adjustments.

CONTRAINDICATIONS

Contraindications include known hypersensitivity to IGF-1 LR3 or any component of the formulation. Not recommended for individuals with active cancer or recent malignancy history, as IGF-1 stimulates cell proliferation in all tissues. Use with extreme caution in individuals with diabetes or glucose intolerance—frequent blood glucose monitoring essential. Those with renal or hepatic impairment should avoid use or use under close medical supervision. Not for use during pregnancy or lactation due to insufficient safety data and potential effects on fetal development. Individuals under 21 years of age should avoid use due to potential effects on growth plates. Those with cardiac conditions should consult a healthcare provider before use.

OVERDOSE

Acute overdose primarily manifests as severe hypoglycemia with symptoms including dizziness, confusion, sweating, tremors, and potential loss of consciousness. Other overdose symptoms may include severe joint pain, significant fluid retention, and organ discomfort. In cases of hypoglycemia, administer fast-acting carbohydrates immediately (glucose tablets, juice, honey) and monitor blood glucose closely. For non-hypoglycemic overdose symptoms, discontinue use and allow the peptide to clear from the system (approximately 20-30 hours). Medical attention may be necessary for severe hypoglycemia. The peptide's extended half-life means effects persist longer than native IGF-1. Always have fast-acting carbohydrates available when using IGF-1 LR3, especially when beginning treatment or adjusting doses.

WARNINGS AND SPECIAL PRECAUTIONS FOR USE

Always have fast-acting carbohydrates available when administering IGF-1 LR3 to address potential hypoglycemia. Monitor blood glucose levels regularly, especially during initial use and dose adjustments. Use proper reconstitution solution (bacteriostatic acetic acid preferred) to maintain peptide stability. Rotate injection sites regularly to prevent lipohypertrophy or tissue irritation. Avoid concurrent use with other hypoglycemic agents unless under medical supervision. Regular monitoring of organ size (via ultrasound) recommended with prolonged high-dose use. Discontinue use 4 weeks before any surgery due to potential effects on wound healing and cell proliferation. Store reconstituted solution refrigerated at 2-8°C and use within 20 days when using acetic acid solution.

INTERACTIONS WITH OTHER DRUGS

Potentiates effects of insulin and other hypoglycemic agents—extreme caution required. May interact with growth hormone and GHRPs, potentially amplifying effects on IGF-1 levels. Corticosteroids may antagonize some anabolic effects. Concurrent use with beta-agonists (like Clenbuterol) may enhance fat loss but also increase hypoglycemia risk. Alcohol increases hypoglycemia risk and should be avoided around administration times. Anabolic steroids may have synergistic effects on muscle growth but also increase potential side effects. Always disclose all medications and supplements to healthcare providers when using IGF-1 LR3. Those using diabetes medications require particularly close monitoring and possible dose adjustments.

PRESENTATION, PACKAGING

Dragon Pharma IGF-1 LR3 1 mg is presented in sterile 2 mL glass vials with gray rubber stoppers and black aluminum seals. Each vial contains 1 mg of lyophilized IGF-1 LR3 powder. Product is available in packs of 5 or 10 vials, often with bacteriostatic acetic acid (0.6%) included for optimal reconstitution. Each vial is individually labeled with product name, strength (1 mg/vial), batch number, expiration date, and unique serial number for authenticity verification. Packaging includes tamper-evident features and discreet outer packaging for privacy. Special reconstitution and handling instructions are included, emphasizing the importance of acetic acid for maintaining peptide stability and biological activity.

STORAGE

Store unopened vials at -20°C to -80°C for long-term storage (over 1 month) or at 2-8°C (36-46°F) for short-term use. Do not expose to repeated freeze-thaw cycles. After reconstitution with bacteriostatic acetic acid, store at 2-8°C (36-46°F) and use within 20 days. When reconstituted with bacteriostatic water only, use within 7 days. Do not use if solution appears cloudy, discolored, or contains particulate matter. Protect from light exposure. For travel, use insulated containers with cold packs or dry ice for frozen transport. Shelf life of unopened vials is 24 months when stored frozen. Keep out of reach of children and pets.

DELIVERY TO THE USA

All orders to the United States are shipped discreetly with guaranteed temperature-controlled delivery. We utilize specialized cold-chain shipping with temperature monitoring devices to ensure peptide integrity during transit. Most orders arrive within 7-10 business days with tracking and temperature data provided. Packaging is plain, unmarked, and includes insulated containers with cold packs for optimal temperature maintenance. We offer reshipment guarantee for orders lost in transit or compromised by temperature excursions. Express shipping options (3-5 business days) with enhanced cold-chain protection available. All packages require signature confirmation. Domestic reshipping services available for added privacy protection.

LEGAL STATUS

In the United States, IGF-1 LR3 is classified as a Schedule III controlled substance under the Anabolic Steroids Control Act when intended for human use. It is illegal to purchase, sell, or possess with intent for human consumption without a prescription. However, it is legal to purchase for research purposes by qualified institutions. This product is sold for laboratory research only. Not for human consumption, diagnosis, or treatment of any disease. Purchasers assume all responsibility for compliance with local, state, and federal laws. In sports competitions, all major organizations prohibit IGF-1 use. Always consult with appropriate legal counsel regarding the status in your jurisdiction.

DATE OF LAST TEXT CHECKS

/

NAME AND ADDRESS OF THE MANUFACTURER

Dragon Pharma, Europe

EXTERNAL LINKS

• National Institutes of Health - IGF-1 Mechanisms in Muscle Growth Review

PROFILE

• Chemical name: Insulin-Like Growth Factor 1 Long R3 Analog
• Chemical formula: C₄₀₂H₆₄₈N₁₁₂O₁₂₀S₈
• Molecular weight: 9100-9200 g/mol (varies by glycosylation)
• Percentage of anabolic activity: Very high (direct anabolic)
• Percentage of androgenic activity: 0% (not androgenic)
• Active half life: 20-30 hours (due to reduced IGFBP binding)
• Recommended dosage: 20-80 mcg daily
• Acne: Possible (via increased growth factors)
• Bloating (water retention): Common, especially at higher doses
• HBR (Hepatobiliary-related): Possible organ enlargement with abuse
• Hepatic toxicity: Low at therapeutic doses
• Aromatization: Does not aromatize
• Detection time: 3-7 days
• Anabolic/Androgenic Ratio: N/A (not anabolic steroid)
• IGFBP binding affinity: ~1% of native IGF-1
• Amino acid length: 83 amino acids (70 native + 13 extension)

Third Party Lab Test

2024-01-19

View Result

1.05 mg